Progress in β receptor-blocker treatment in chronic obstructive pulmonary disease complicated with cardiovascular diseases
10.3969/j.issn.1008-0074.2024.03.25
- VernacularTitle:β受体阻滞剂在慢性阻塞性肺疾病合并心血管疾病中的治疗进展
- Author:
Yu-Qian YUE
1
;
Fu-Hui CHEN
Author Information
1. 哈尔滨医科大学附属第二医院呼吸内科,黑龙江哈尔滨 150081
- Keywords:
Pulmonary disease,chronic obstructive;
Cardiovascular diseases;
Adrenergic beta-antagonists
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2024;33(3):361-364
- CountryChina
- Language:Chinese
-
Abstract:
β-receptor blockers are used to treat cardiovascular disease(CVD),while β-receptor agonists are used to treat chronic obstructive pulmonary disease(COPD).The two drugs have opposite mechanisms of action.Howev-er,there is a close relationship between COPD and CVD,and CVD is related to the severity of pulmonary dysfunc-tion.The use of β-receptor blockers in COPD is still controversial,but studies have shown that cardiac selective β-receptor blockers can reduce mortality in mild and moderate COPD with CVD and reduce the risk of COPD exacerbation,while non-selective β-receptor blockers increase the risk of COPD exacerbation.However,the dosage of cardiac selective β-receptor blockers and its balance with β-receptor agonists in COPD patients with CVD still requires serious treatment.Research on new β-receptor blockers is a problem to be paid close attention to in the future.
